Charmaine S Ng1, Joyce Y C Lee1, Matthias Phs Toh2, Yu Ko3. 1. Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, Singapore. 2. Information Management, Corporate Development, National Healthcare Group, Singapore, Singapore; Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore. 3. Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, Singapore. Electronic address: nancykotw@gmail.com.
Abstract
BACKGROUND: Diabetes mellitus (DM) is recognised as a major health problem. OBJECTIVES: The aims of this study are two-fold: (1) to describe the methods used in the identified cost-of-illness (COI) studies of DM and (2) to summarise their study findings regarding the economic impact of DM. METHODS: This is a systematic review of MEDLINE and Scopus journal articles reporting the cost of type 1 and/or 2 DM that were published in English from 2007 to 2011. Costs reported in the included studies were converted to US dollars. RESULTS: The systematic search yielded 30 articles. The studies varied considerably in their study design, perspective and included cost categories. Estimates for the total annual costs of DM ranged from US$141.6 million to US$174 billion; direct costs ranged from US$150 to US$14,060 per patient per year (pppy) whereas indirect costs ranged from US$39.6 to US$7,164 pppy. Inpatient cost was the major contributor to direct cost in half of the studies that included inpatient costs, physician services and medications. CONCLUSION: There is a considerable economic burden associated with DM. Future research should focus on improving methods of estimating costs, enhancing the interpretation of study findings and facilitating comparisons between studies.
BACKGROUND:Diabetes mellitus (DM) is recognised as a major health problem. OBJECTIVES: The aims of this study are two-fold: (1) to describe the methods used in the identified cost-of-illness (COI) studies of DM and (2) to summarise their study findings regarding the economic impact of DM. METHODS: This is a systematic review of MEDLINE and Scopus journal articles reporting the cost of type 1 and/or 2 DM that were published in English from 2007 to 2011. Costs reported in the included studies were converted to US dollars. RESULTS: The systematic search yielded 30 articles. The studies varied considerably in their study design, perspective and included cost categories. Estimates for the total annual costs of DM ranged from US$141.6 million to US$174 billion; direct costs ranged from US$150 to US$14,060 per patient per year (pppy) whereas indirect costs ranged from US$39.6 to US$7,164 pppy. Inpatient cost was the major contributor to direct cost in half of the studies that included inpatient costs, physician services and medications. CONCLUSION: There is a considerable economic burden associated with DM. Future research should focus on improving methods of estimating costs, enhancing the interpretation of study findings and facilitating comparisons between studies.
Authors: Elizabeth Murray; Eric B Hekler; Gerhard Andersson; Linda M Collins; Aiden Doherty; Chris Hollis; Daniel E Rivera; Robert West; Jeremy C Wyatt Journal: Am J Prev Med Date: 2016-11 Impact factor: 5.043
Authors: Charbel El Bcheraoui; Mohammed Basulaiman; Marwa Tuffaha; Farah Daoud; Margaret Robinson; Sara Jaber; Sarah Mikhitarian; Ziad A Memish; Mohammad Al Saeedi; Mohammad A AlMazroa; Ali H Mokdad Journal: Int J Public Health Date: 2014-10-08 Impact factor: 3.380
Authors: Paulo José Basso; Lucas Favaretto Tazinafo; Mauro Ferreira Silva; Maria José Alves Rocha Journal: Adv Physiol Educ Date: 2014-09 Impact factor: 2.288
Authors: Fatima Ochoa-Gonzalez; Alberto R Cervantes-Villagrana; Julio C Fernandez-Ruiz; Hilda S Nava-Ramirez; Adriana C Hernandez-Correa; Jose A Enciso-Moreno; Julio E Castañeda-Delgado Journal: PLoS One Date: 2016-03-10 Impact factor: 3.240